Literature DB >> 27677636

Cancer Drugs Fund requires further reform.

Richard Grieve1, Keith Abrams2, Karl Claxton3, Ben Goldacre4, Nicholas James5, Jon Nicholl6, Mahesh Parmar7, Chris Parker8, Jasjeet S Sekhon9, Liam Smeeth10, David Spiegelhalter11, Mark Sculpher3.   

Abstract

Entities:  

Year:  2016        PMID： 27677636     DOI： 10.1136/bmj.i5090

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  The Cancer Drugs Fund in Practice and Under the New Framework.

Authors:  Celia Sabry-Grant; Kinga Malottki; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

3.  The New and Non-Transparent Cancer Drugs Fund.

Authors:  Eifiona M Wood; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

Review 4.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

5.  Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Authors:  Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; László Szilberhorn; Tamás Zelei; Balázs Nagy; Rositsa Koleva-Kolarova; Apostolos Tsiachristas; Sarah Wordsworth; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2021-04-16       Impact factor: 4.981

6.  Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Authors:  Liz Morrell; Sarah Wordsworth; Anna Schuh; Mark R Middleton; Sian Rees; Richard W Barker
Journal:  BMC Health Serv Res       Date:  2018-05-31       Impact factor: 2.655

7.  Coverage with evidence development for medical devices in Europe: Can practice meet theory?

Authors:  Michael Drummond; Carlo Federici; Vivian Reckers-Droog; Aleksandra Torbica; Carl Rudolf Blankart; Oriana Ciani; Zoltán Kaló; Sándor Kovács; Werner Brouwer
Journal:  Health Econ       Date:  2022-02-26       Impact factor: 2.395

Review 8.  Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.

Authors:  Matthew Franklin; James Lomas; Gerry Richardson
Journal:  Pharmacoeconomics       Date:  2020-07       Impact factor: 4.981
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.